Drug Profile


Alternative Names: R 228060; YKP10A

Latest Information Update: 29 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK Bio-Pharmaceuticals; SK Corporation
  • Developer Janssen; SK biopharmaceuticals; SK Holdings
  • Class Antidepressants; Sleep disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported CNS disorders; Major depressive disorder; Narcolepsy; Neuropathic pain

Most Recent Events

  • 29 Sep 2011 No development reported - Preclinical for CNS disorders in USA (PO)
  • 29 Sep 2011 No development reported - Preclinical for Narcolepsy in USA (PO)
  • 29 Sep 2011 No development reported - Preclinical for Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top